Hyperhomocysteinemia and cardiovascular diseases

Ann Biol Clin (Paris). 2022 Feb 1;80(1):7-14. doi: 10.1684/abc.2021.1694.

Abstract

Homocysteine (Hcy) is a sulfhydryl-containing amino acid, which is not acquired through the diet, but rather synthesized as an intermediate metabolite in the methionine cycle. Hcy is present in plasma, with normal levels between 5 and 15 μmol/L, a slightly elevated level between 15 to 30 μmol/L, moderate from 30 to 100 μmol/L and a value > 100 μmol/L classified as severe hyperhomocysteinemia (HHcy). HHcy has been associated with inflammation and atherosclerosis and is considered an independent risk factor for cardiovascular diseases (CVD). Here, we review the main evidence showing the association and the possible involvement of HHcy in the most common CVD.

Keywords: cardiovascular; homocysteine; hyperhomocysteinemia.

Publication types

  • Review

MeSH terms

  • Cardiovascular Diseases* / diagnosis
  • Cardiovascular Diseases* / epidemiology
  • Cardiovascular Diseases* / etiology
  • Homocysteine
  • Humans
  • Hyperhomocysteinemia* / complications
  • Hyperhomocysteinemia* / diagnosis
  • Inflammation
  • Methionine
  • Risk Factors

Substances

  • Homocysteine
  • Methionine